Target Price | $399.33 |
Price | $330.87 |
Potential |
20.69%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Bio-Rad Laboratories, Inc. Class B 2025 .
The average Bio-Rad Laboratories, Inc. Class B target price is $399.33.
This is
20.69%
register free of charge
$481.00
45.37%
register free of charge
$315.00
4.80%
register free of charge
|
|
A rating was issued by 8 analysts: 5 Analysts recommend Bio-Rad Laboratories, Inc. Class B to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Bio-Rad Laboratories, Inc. Class B stock has an average upside potential 2025 of
20.69%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Billion $ | 2.67 | 2.58 |
4.67% | 3.45% | |
EBITDA Margin | 21.57% | 18.17% |
7.93% | 15.76% |
6 Analysts have issued a sales forecast Bio-Rad Laboratories, Inc. Class B 2024 . The average Bio-Rad Laboratories, Inc. Class B sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Bio-Rad Laboratories, Inc. Class B EBITDA forecast 2024. The average Bio-Rad Laboratories, Inc. Class B EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
EV/Sales | 3.50 |
Based on analysts' sales estimates for 2024, the Bio-Rad Laboratories, Inc. Class B stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Bio-Rad Laboratories, Inc. Class B...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.